Efficacy outcomes
The full analysis showed that, compared with the baseline, all the 1% and 2% rebamipide groups and the placebo group showed significantly improved TBUT, corneal fluorescein staining scores, conjunctival lissamine green staining scores, and OSDI after 12 weeks of treatment (all 
Comparison of tear break-up time 
Comparison of efficacy outcomes between study groups in the full-analysis set (n = 220)1% rebamipidevs. Placebo2% rebamipidevs. Placebo1% rebamipidevs. Placebo2% rebamipidevs. Placebo1% rebamipidevs. Placebo2% rebamipidevs. Placebo1% rebamipidevs. Placebo2% rebamipidevs. Placebo1% rebamipidevs. Placebo2% rebamipidevs. Placebo* Wilcoxon rank sum test† Paired ‡ Wilcoxon signed rank testThe per protocol analysis showed that all participants in the 1% and 2% rebamipide groups and the placebo group showed significantly improved TBUT, corneal fluorescein staining scores, conjunctival lissamine green staining scores, and OSDI after 12 weeks of treatment (
Comparison of efficacy outcomes between study groups in the per-protocol set (n = 189)1% rebamipidevs. Placebo2% rebamipidevs. Placebo1% rebamipidevs. Placebo2% rebamipidevs. Placebo1% rebamipidevs. Placebo2% rebamipidevs. Placebo1% rebamipidevs. Placebo2% rebamipidevs. Placebo1% rebamipidevs. Placebo2% rebamipidevs. Placebo* Wilcoxon rank sum test† Paired ‡ Wilcoxon signed rank test